VBWG

Event

Select Event:

Is It Time for Cardiology to Embrace Novel Therapeutic Options in Diabetes?

Steven P. Marso, MD, FACC
HCA Midwest Health
Kansas City, MO

Renal Denervation for Hypertension: Is it Back?

Michael Böhm, MD, PhD, FESC
Saarland University Medical Center
Homburg, Germany

Expanding Indications for Direct Oral Anticoagulants

Michael Ezekowitz, MBChB, DPhil, FACC
Thomas Jefferson University Hospital
Philadelphia, PA

New Approaches to Pulmonary Hypertension: Why Aren’t More Cardiologists Interested in PAH?

Mardi Gomberg-Maitland, MD, MSc, FACC
Inova Heart and Vascular Institute
Falls Church, VA

Prevention and Monitoring of Cardiac Dysfunction in Cancer Patients

Anju Nohria, MD, MSc
Brigham and Women’s Hospital
Boston, MA

Immune Checkpoint-associated Myocarditis: A New Entity in Cardio-Oncology

Javid J. Moslehi, MD
Vanderbilt School of Medicine
Nashville, TN

Adipose-derived Cell-based Therapies for CVD: From Cells to Secretome

Keith March, MD, PhD, FACC
University of Florida College of Medicine
Gainesville, FL

ORBITA Redux / To Stent or Not: Yes, Revascularization is Still Standard of Care

Ajay J. Kirtane, MD, FACC
Columbia University Medical Center
New York, NY

Emerging Approaches to Dyslipidemia Management Beyond LDL-C

Eliot A. Brinton, MD, FAHA, FNLA
Utah Lipid Center
Salt Lake City, UT

Integrating Big Data with Evidence Generation for Precision Medicine: Implications for Cardiovascular Disease.

Elliott M. Antman, MD, MACC
Immediate Past President AHA
Harvard Medical School
Boston, MA

Treating HTN Today: Insights from SPRINT and the New Clinical Practice Guidelines for Patients with CAD.

Clive Rosendorff, MD, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Cardiovascular Outcomes with Medicines to Control Glycemia: Highlights from Recently Completed Trials.

Darren K. McGuire, MD, MHSc
UT Southwestern Medical Center
Dallas, TX

Where Are We With Systolic Heart Failure?

Ileana Pina, MD, MPH
Montefiore Medical Center
Bronx, NY

Are We Back to Lower is Better: Time to Revise the 2014 Guidelines?

Stephen D. Wiviott,  MD
Brigham and Women’s Hospital
Boston, MA 

New Directions in Antiplatelet Therapy

David A. Morrow, MD, MPH
Brigham and Women’s Hospital
Boston, MA

Impacting Lipid Disorders Through Personalized Healthcare: What the Future Holds.

Daniel J. Rader, MD
University of Pennsylvania School of Medicine
Philadelphia, PA

Personalized Medicine in Patients with Coronary Artery Disease.

Jean-Claude Tardif, , MD
Montreal Heart Institute
Montreal, QC, Canada

The Future of Healthcare and the Role of the National Academy of Medicine.

Victor J. Dzau, MD
National Academy of Medicine
Washington, DC

Molecular Imaging in the Era of Personalized Medicine.

Mehran Sadeghi, MD
Yale University School of Medicine
New Haven, CT

NOACS for Valve Disease?

A. John Camm, MD
St. George’s University Hospital
London, UK

New Oral Interventions for Heart Failure.

Javed Butler,  MD, MPH
Stony Brooke University School of Medicine
Stony Brook, NY

Beyond Statins: The Coming Revolution in Lipid Therapy

Christie Ballantyne, MD
Baylor College of Medicine
Houston, TX

Cell Therapy: Where Are We Today and Where Are We Headed?

Eduardo Marban, MD, PhD
Cedars-Sinai Hospital
Los Angeles, CA

Bariatric Surgery for Obesity and Cardiometabolic Conditions: Time to Embrace?

Michael E. Farkouh, MD, MSc
University of Toronto
Toronto, ON, Canada 

Where Are We With Diastolic Heart Failure?

Christopher O’Connor, MD
Duke University Medical Center
Durham, NC

The Rapidly Evolving Field of TAVR

John G. Webb, MD
St. Paul’s Hospital
Vancouver, BC, Canada

Percutaneous MVR After Everest II: What the Future Holds

Ted E. Feldman, MD
NorthShore University HealthSystem
Evanston, IL

Heart Disease in Women: Have We Made Progress?

C. Noel Bairey Merz, MD
Cedars-Sinai Hospital

Managing Type 2 Diabetes: New and Future Developments in Treatment

Silvio E. Inzucchi, MD
Yale School of Medicine

New Developments in the Treatment of Heart Failure

John J. McMurray, MD
University of Glasgow

New Frontiers in Cardiac Biomarkers

Alan S. Maisel, MD
University of California San Diego

PCSK9 and Atherosclerosis: Will We Target Risk with Monoclonal Antibodies or Only LDL-C?

Michael J. Koren, MD
Jacksonville Ctr. For Clinical Research

HDL Dysfunction in Coronary Artery Disease: An Enigma or Dead?

Stephen J. Nicholls, MBBS, PhD
South Australian Health and Medical Research Institute

Emerging Therapies on the Horizon for Hypertriglyceridemia

Ira Goldberg, MD
NYU Langone Medical Center

Is Left Atrial Occlusion Really an Alternative to Lifelong Anticoagulation?

David R Holmes Jr. MD, Mayo Clinic, Rochester, MN

Turning White Fat to Brown: Foe to Friend or Not?

Jorge Plutzky MD, Brigham and Women's Hospital

Serelaxin: Breakthrough Therapy or Also-ran?

John R Teerlink MD, UCSF School of Medicine

A Novel Approach to Preventing Aortic Stenosis

Jean-Claude Tardif MD, Montreal Heart Institute

Future Pharmacological Options for Heart Failure

Christopher O'Connor MD, Duke University Medical Center